asco前列腺癌—潘月龙

Р转移程度低疾病Р转移程度高疾病Р内脏转移+/-骨转移Р转移程度高(仅骨转移)Р白人Р其他种族РGleason评分<8РGleason评分≥8Р既往局部治疗—否Р既往局部治疗—是РCAB>30天—否РCAB>30天—是РSRE—否РSRE—是Р790Р患者数Р612Р178Р276Р514Р125Р387Р674Р92Р220Р480Р575Р214Р459Р331Р443Р347Р0.61РHRР0.68Р0.43Р0.63Р0.60Р0.48Р0.65Р0.62Р0.53Р0.41Р0.60Р0.66Р0.55Р0.69Р0.52Р0.58Р0.65Р0.47-0.80Р95%CIР0.50-0.91Р0.23-0.78Р0.34-1.17Р0.45-0.81Р0.23-0.99Р0.48-0.91Р0.47-0.83Р0.17-1.60Р0.21-0.80Р0.43-0.84Р0.50-0.89Р0.23-1.31Р0.49-0.99Р0.34-0.79Р0.40-0.84Р0.45-0.96РADT+D更好РADT更好РSweeney C, et al. 2014 ASCO Abstract LBA2.Р8РSlide 1РPresented By Nicholas James at 2015 ASCO Annual MeetingРRationale for study agentsРPresented By Nicholas James at 2015 ASCO Annual MeetingР研究药物选择依据:? 多系紫杉醇:? 可以延长去势抵抗转移性前列腺癌生存期;? 老年人也有较好的耐受性? 唑来膦酸:? 降低去势抵抗转移性前列腺癌骨相关事件的发生? 系列研究把唑来膦酸作为预防转移的药物Р 联合治疗:? 体外有证据支持二者有协调作用? 预期二者联合耐受性良好